Epigenetic modifications, such as DNA methylation, are widely studied in cancer as they are stable and easy to measure genome wide. DNA methylation changes have been used to differentiate benign from malignant tissue and to predict tumor recurrence or patient outcome. Multiple genome wide DNA methylation studies in breast and prostate cancers have identified genes that are differentially methylated in malignant tissue compared with non-malignant tissue or in association with hormone receptor status or tumor recurrence. Although this has identified potential biomarkers for diagnosis and prognosis, what is highlighted by reviewing these studies is the similarities between breast and prostate cancers. In particular, the gene families/pathways targeted by DNA methylation in breast and prostate cancers have significant overlap and include homeobox genes, zinc finger transcription factors, S100 calcium binding proteins, and potassium voltage-gated family members. Many of the gene pathways targeted by aberrant methylation in breast and prostate cancers are not targeted in other cancers, suggesting that some of these targets may be specific to hormonal cancers. Genome wide DNA methylation profiles in breast and prostate cancers will not only define more specific and sensitive biomarkers for cancer diagnosis and prognosis but also identify novel therapeutic targets, which may be direct targets of agents that reverse DNA methylation or which may target novel gene families that are themselves DNA methylation targets.
Introduction
Numerous diseases are associated with abnormal hormonal regulation including breast and prostate cancers. Breast cancer is a heterogeneous disease that can be classified in many ways. The most primary classification is by hormone receptor status, namely estrogen receptor a (ERa) and progesterone receptor (PR), with more recent recognition that the androgen receptor (AR) is also important. Hormone receptor status of breast cancer is critical because it directs clinical decisions about adjuvant hormone therapy. ERa-positive tumors are responsive to anti-estrogenic treatments, including selective ER modulators like tamoxifen or aromatase inhibitors, which have significantly increased the odds of survival from this disease. However, w30% of women have ERa-negative tumors, and currently, there are no established hormone therapies for the clinical management of women with ERa-negative breast cancers.
Prostate cancer is also a heterogeneous disease and, if diagnosed early, is potentially curable by surgery and/or radiotherapy. However, up to 20% of patients will relapse with metastatic disease within 5-10 years. The main therapy for patients with locally advanced or metastatic disease targets androgen production and its receptor. These therapies result in an initial period of tumor regression; however, eventually, prostate cancers become unresponsive and progress to the castrate-resistant state. Current therapies for advanced prostate cancer are not curative and there are limited treatment options for patients that develop castrate-resistant prostate cancer (CRPC) .
Although the role of hormone receptors in breast and prostate cancers is well established and utilized for therapeutic treatments, new targets are needed for hormone-resistant disease in breast and prostate cancers. Epigenetic modifications are critical events in tumorigenesis and, in comparison to somatic mutations, occur at a much higher frequency. Epigenetic modifications are reversible changes to the genome and therefore are excellent therapeutic targets. Epigenetic modifications like DNA methylation are also stable and technically easy to assess making them ideal biomarkers for diagnosis and prognosis. It is well established from candidate gene studies that epigenetic modifications play an important role in hormone-dependent cancers (Chin et al. 2011 , Jeronimo et al. 2011 , Huynh et al. 2012 ; however, it is essential to expand our knowledge of epigenetic modifications that may occur commonly in hormonally responsive disease states. In this review, we focus on genome wide DNA methylation studies in breast and prostate cancers and in particular the overlap in aberrantly methylated genes in these hormonally regulated cancers.
DNA methylation
Unlike mutations that alter the DNA sequence, epigenetic modifications regulate gene expression via chromatin remodeling. The most studied epigenetic modification is DNA methylation, which is critical during embryogenesis, imprinting, and X chromosome inactivation (Jaenisch & Bird 2003 , Salozhin et al. 2005 , Nafee et al. 2008 . DNA methylation involves the transfer of a methyl group from methyl donor S-adenosylmethionine to the 5 0 carbon of cytosine. This occurs predominantly at CpG. CpG islands, which are clusters of CpGs (O55%), are frequently found within gene promoter regions. Methylation of promoterassociated CpG islands is often linked to gene repression, either through a direct or indirect influence on the chromatin structure resulting in chromatin condensation (Chan et al. 2000 , Nakao 2001 , Salozhin et al. 2005 .
DNA methylation and cancer
DNA methylation is important in maintaining the integrity of the genome, and so it is hardly surprising that alterations in DNA methylation are commonly associated with disease. Numerous studies have supported the important role of DNA methylation in carcinogenesis (reviewed in Baylin & Jones (2011) ), have shown that targeting aberrant DNA methylation is a promising cancer therapeutic (Baylin & Jones 2011) , and demonstrated that DNA methylation can act as a disease biomarker (Jovanovic et al. 2010 , Jeronimo et al. 2011 , Chiam et al. 2012 , Sandoval & Esteller 2012 . Alterations in DNA methylation have been observed in multiple cancers, with global hypomethylation occurring simultaneously with gene-specific promoter hypermethylation (Esteller 2005 , Karpinets & Foy 2005 , Baylin & Ohm 2006 . Global hypomethylation has been linked to activation of proto-oncogenes and chromosomal instability (Hake et al. 2004 , Szyf et al. 2004 , Szyf 2005 . In contrast, gene-specific hypermethylation is associated with inactivation of genes involved in DNA repair, cell cycle regulation, apoptosis, and tumor suppression (Esteller 2005 , Miyamoto & Ushijima 2005 , Baylin & Ohm 2006 .
Methods
This is a systematic review of genome wide DNA methylation studies in breast and prostate cancers, as reported on PubMed at May 2013. All studies with an unbiased genome wide DNA methylation analysis conducted in human breast and/or prostate cancer tissue, or cell lines derived from these tissues, were included. Cell line studies were included only if they analyzed at least two independent cell lines. We define 'unbiased' as techniques with no selection of genomic regions analyzed based on function, structure, or any other knowledge of genes or regions. Techniques that analyze only gene promoter CpG islands are included, although we acknowledge that these methods are selective by their nature. Genome wide techniques are those that assess methylation on a global scale, usually at least 10 000 CpG sites, and where the methylation status can be linked to a genomic location. Gene expression and chromosome copy number analysis of the same samples will be discussed, where available. Studies investigating genome wide changes in gene expression after treatment with demethylating agents, but without corresponding genome wide DNA methylation data, were excluded on the basis that these studies include both primary (direct) and secondary (indirect) effects of demethylation. The search term 'DNA methylation profiling cancer breast' retrieved 180 references and 'DNA methylation profiling cancer prostate' retrieved 56 references on 6th May 2013. Some of the papers reviewed here were not retrieved by these search terms in PubMed but were identified from reviewing the selected papers. In total, 22 breast cancer and ten prostate cancer studies fitted our genome wide, unbiased criteria. The techniques used for genome wide DNA methylation analysis in breast or prostate cancer have been comprehensively reviewed elsewhere (Laird 2010 ) and therefore will not be discussed in this review.
Limitations and biases of genome wide DNA methylation techniques
Many techniques for genome wide methylation analysis do not assess DNA methylation equally across the entire genome, instead focusing on CpGs within islands or gene promoters. In breast cancer, Novak et al. (2008) , using methyl DNA immunoprecipitation (IP) followed by a promoter array, found that hypermethylation (38%) was more frequent than hypomethylation (6%) in differentially methylated regions (DMRs) between tumor vs normal. However, methyl DNA IP is biased for hypermethylated DNA. Similarly, Ordway et al. (2007) found that hypermethylation is more frequent than hypomethylation in breast cancer compared with nonmalignant tissue. Ordway et al. (2007) digested DNA with McrBC, which has loose site specificity, allowing for the analysis of regional DNA methylation density. Samples were hybridized to OGHAv1.0 microarray (Ordway et al. 2006) , which predominantly covers promoter regions and transcription start sites. Both these studies predominantly analyzed promoter regions rather than analyzing equally across the entire genome. Hu et al. (2005) used methylation-specific digital karyotyping (MSDK) to identify that in breast, tumor stromal and epithelial cells were hypomethylated relative to normal stromal and epithelial cells. The MSDK technique is biased for CpG islands, but regions analyzed are distributed across the genome rather than clustered around transcription start sites. Friedlander et al. (2012) reported hypermethylation in CRPC relative to benign prostate using the Illumina Infinium HumanMethylation27 BeadChip. This was more pronounced for CpG islands but was common across all areas of the genome analyzed, although the HumanMethylation27 BeadChip predominantly assesses CpGs in gene proximal promoters. Similarly, Kim et al. (2011c) observed overall hypermethylation in cancer using the same platform. In contrast, in the same study, ALU elements were hypomethylated in cancer compared with non-malignant tissue (Kim et al. 2011c (Li et al. 2009 , Van der Auwera et al. 2010 , Dedeurwaerder et al. 2011 , Fang et al. 2011 , Kamalakaran et al. 2011 , Sproul et al. 2011 , Sun et al. 2011 ). Flanagan et al. (2010 , using familial breast cancers and BRCA1/2-mutated cancers, combined DNA methylation profiles that alone predicted BRCA status, with gene expression and copy number variation (CNV) and found that genes with reduced expression were more likely to be in genomic regions with loss of heterozygosity and/or high levels of DNA methylation. Using a panel of breast cancer cell lines, it has also been shown that the combination of gene dosage, allelic status, and DNA methylation explains more gene expression changes than either genomic element alone (Chari et al. 2010) . This highlights that in future studies, combining DNA methylation profiling with CNV and gene expression will be an effective tool to facilitate the identification of critical genes involved in tumorigenesis. Similarly, in prostate cancer, Kim et al. (2011a) demonstrated that gene promoter methylation was associated with gene under-expression, irrespective of the presence of a CpG island, while coding exon methylation was associated with over-expression. A study by Friedlander et al. (2012) also supported the correlation between DNA methylation and gene expression, in this case also integrating chromosome copy number across metastatic CRPC compared with primary cancer and benign prostate tissue. Together, these studies in breast and prostate cancers demonstrate that the functional effects of gene silencing, initially identified for a small subset of candidate genes, can be identified by genome wide DNA methylation studies. Thus, future genome wide DNA methylation studies can provide an additional avenue to identify novel genes silenced by DNA methylation in tumorigenesis.
Genome wide DNA methylation in breast cancer DNA methylation profiles discriminate tumor from non-malignant breast tissue Genome wide DNA methylation has been extensively applied to discriminate between tumor and normal or histologically non-malignant breast tissue. One of the first genome wide DNA methylation studies in breast cancer developed MSDK to assess epithelial, myoepithelial, and stromal fibroblasts from normal and cancer breast tissues (Hu et al. 2005 ; Table 1 ). Although there were few differences between tumor and normal myoepithelial cells, DNA hypomethylation frequency was higher in tumor epithelial and stromal cells when compared with normal cells of the same subtype (Hu et al. 2005) . Based on DNA methylation profiles, Ordway et al. (2007) identified 220 loci that differentiated non-malignant from tumor tissue, with hypermethylation more common than hypomethylation (Table 1) . Validation was performed for 53 hypermethylated loci in 16 infiltrating ductal carcinomas and 25 normal or benign breast tissues (Ordway et al. 2007) . Sixteen DMRs were also identified with O95% specificity between breast cancer (103 tumors) and nonmalignant breast tissue and blood (Ordway et al. 2007) , suggesting that tissue type was not critical for methylation detection. Differential methylation in tumors was not significantly associated with age, hormone receptor status, or family history (Ordway et al. 2007) . Differential methylation of one marker, GHSR, distinguished cancer from normal with 90% sensitivity and 96% specificity (Ordway et al. 2007) . In future, combining multiple markers with high specificity and sensitivity into a biomarker panel may assist in developing a clinical test to accurately differentiate breast tumor tissue from non-malignant. Novak et al. (2008) utilized a promoter array after methyl DNA IP with 5-methyl-cytosine antibody (MeDIP) and found more hypermethylated (2033) than hypomethylated (1473) DMRs in cancer compared with normal breast tissue (Table 1) . A similar study compared ductal carcinomas in situ to non-malignant tissue with a CpG island array after IP (Tommasi et al. 2009 ; Table 1 ). In this study, O100 CpG islands were significantly altered in tumor compared with non-malignant tissue. These islands were positively methylated in O50% of cancer samples. This demonstrates that not only can tumor tissue be differentiated from non-malignant using DNA methylation but also that hypermethylation can easily be distinguished from hypomethylation. Van der Auwera et al. (2010) Kamalakaran et al. (2011) identified several hundred differentially methylated loci between 11 adjacent nonmalignant breast tissues and 108 tumors (Table 1) . Kim et al. (2011b) pooled DNA from ten cancers and ten nonmalignant matched adjacent tissues and identified 1181 differentially methylated CpGs (corresponding to 1043 genes) with the vast majority (972) hypermethylated (Table 1) . Hill et al. (2011) found 291 probes (264 genes) hypermethylated in breast cancer (nZ39) compared with non-malignant breast tissue (nZ4) after removal of imprinted genes and X chromosome genes (Table 1) . Additional studies have also compared tumor to nonmalignant tissue and the number of genes identified that discriminates the two depends on the filtering or analyses utilized. For example, Kim et al. (2012) used several filtering processes to identify six genes, whereas Faryna et al. (2012) identified 214 CpG islands but only one CpG island (TAC1) was methylated in all ten cancer samples. The identification of thousands of loci with altered DNA methylation between non-malignant and tumor tissue using genome wide methylation analyses raises several (Li et al. 2010 , Dedeurwaerder et al. 2011 , Fang et al. 2011 , Hill et al. 2011 , Sun et al. 2011 , although a study by Van der Auwera et al. (2010) did not find any association between hormone receptor status and DNA methylation profile (Table 1) . It is important to note that there were several methodological differences between these studies, such as how the clustering analysis was performed and whether information from all CpG sites were used or only highly methylated CpG sites. These methodological differences may explain the different results reported. Likewise, the No correlation between methylation and molecular subtype MSDK, methylation-specific digital karyotyping; MMSDK, modified MSDK; MOMA, methylation oligonucleotide microarray analysis; PRC2, polycomb complex 2; 5-aza, 5-aza-2 0 -deoxycytidine; BCa, breast cancer; CNV, copy number variation; CGH, comparative genomic hybridization; DCIS, ductal carcinoma in situ; DMH, differential methylation hybridization; DMR, differentially methylated regions; ER, estrogen receptor; FFPE, formalin fixed, paraffin embedded; GSEA, gene set enrichment analysis; HMEC, human mammary epithelial cells; HRC, hormone receptor-positive (ERCPRC); HRK, hormone receptor-negative (ERKPRK); IBC, inflammatory breast cancer; IDC, infiltrating ductal carcinoma; IP, immunoprecipitation; IPA, Ingenuity Pathway Analysis; miRNA, microRNA; LOH, loss of heterozygosity; MBD2bt, truncated methyl DNA binding domain; MeDIA, methylated DNA isolation assay; MeDIP, methyl DNA immunoprecipitation using a 5MeC MAB; MIRA, methylated CpG island recovery assay; MSP, methylation-specific PCR; NM, non-malignant; PR, progesterone receptor. If the information was available, details of the type of tissue used were also included. patient cohorts were different between these studies and so this may contribute to the differing outcomes. The majority of genome wide DNA methylation studies have found that ERCPRC tumors have higher levels of DNA methylation compared with ERKPRK tumors (Li et al. 2010 , Fackler et al. 2011 , Fang et al. 2011 , Hill et al. 2011 . Li et al. (2010) found 148 altered CpG sites (93 hypermethylated and 55 hypomethylated) in ERCPRC breast cancers relative to ERKPRK tumors (Table 1) . Fackler et al. (2011) identified 40 CpG probes that had an overall specificity of 89% and sensitivity of 90% for classifying ERC from ERK tumors. Hill et al. (2011) used cluster analysis to show that ERCPRC tumors had high methylation, whereas triple-negative breast cancers had low methylation (Table 1 ). Genome wide DNA methylation studies in breast cancer cell lines have also shown clustering according to hormone receptor status based on DNA methylation levels (Sun et al. 2011) . Most critically, these genome wide DNA methylation studies demonstrate that an adequately powered study of appropriate clinical samples should identify methylation differences based on hormone receptor status. With additional future study, this may serve as a basis for the development of an improved clinical test to identify the hormone status of breast cancers.
Several studies have also assessed DNA methylation and its association with breast cancer subtypes. A study profiling 30 breast cancer cell lines did not find any correlation between methylation and breast cancer subtypes, although the basal cell type was associated with two DNA methylation clusters (Zheng & Zhao 2012) . Dedeurwaerder et al. (2011) identified six DNA methylation clusters and HER2-positive tumors, basal-like and luminal A cancer each belonged to a cluster, but three clusters were not associated with a predominant molecular subtype. Kamalakaran et al. (2011) also performed DNA methylation cluster analysis and found that one cluster was predominantly luminal A (22/30 samples), the second cluster was highly correlated with basal-like (7/8 samples), and the third cluster contained a mixture of subtypes. Recently, The Cancer Genome Atlas assessed DNA methylation profiles in 802 breast cancers and identified that the group with high DNA methylation was associated with the luminal B subtype while the group with low methylation was associated with the basal-like subtype (Table 1; Cancer Genome Atlas N 2012) . Future studies need to include a more detailed investigation of the methylation differences between breast cancer subtypes to determine whether there is a methylation signature that can identify breast cancer subtypes. It is possible that methylation analysis will need to be combined with other genome wide analyses to correctly cluster breast cancer subtypes. It is also possible that DNA methylation subtypes are different to the subtypes identified by gene expression and may provide additional information that assists in the clinical setting. Further research is required to delineate these options and determine how subtypes identified by DNA methylation profiling differ to subtypes identified by gene expression.
DNA methylation profiles and breast cancer prognosis
Identifying biomarkers for breast cancer prognosis by DNA methylation profiling have also been the subject of intensive investigations. One of the first biomarker studies found that when breast cancer samples were divided into high and low DNA methylation levels, the high group was enriched for patients with a poor prognosis (Van der Auwera et al. 2010). Using a clustering approach, Fang et al. (2011) found that the group of breast cancers with high DNA methylation levels was ER/PRC and that this group has a lower risk of relapse and better overall survival. By selecting genes with a strong anti-correlation between DNA methylation and expression status, univariate Cox regression analysis identified 32 genes that were significant prognostic markers in breast cancer (Dedeurwaerder et al. 2011) . Further filtering of these genes identified 11 genes associated with immunity, and high expression of these genes was associated with a good clinical outcome; 10/11 were independent prognostic markers by multivariate analysis (Dedeurwaerder et al. 2011) . Using a genome wide DNA methylation approach on 82 breast cancers, 100 CpGs were associated with recurrence; homeobox genes were enriched in this set of hypermethylated loci (Fackler et al. 2011) . Focusing just on homeobox genes, 60 homeobox loci were associated with recurrence, and these were an independent predictor of recurrence (Fackler et al. 2011) . It is important to note that this study design was biased toward hypermethylated loci.
Using cluster analysis of genome wide DNA methylation data to divide breast cancers into three groups, high, intermediate, and low DNA methylation levels, the high DNA methylation group was associated with relapse but there was no association with disease-free survival with any of the groups (Hill et al. 2011) . However, when the probes/genes associated with a single clinical feature (hormone receptor status, tumor relapse, and lymph node status) were assessed individually using Fisher's exact tests with false discovery rate correction, nine genes were identified that were significantly associated with relapse-free survival (Hill et al. 2011) . This demonstrates the importance of dividing cancers into appropriate groups for analysis. Kamalakaran et al. (2011) identified 2259 loci that divided patients into good and poor prognosis groups; 921 of these remained significant after multivariate and Cox regression analysis. Faryna et al. (2012) , although with a small samples size, identified methylation of two genes associated with metastasis-free survival. Further study should be directed at determining the minimal number of loci required to effectively stratify patients by prognosis. Extensive future work is also required to follow on from all these prognostic studies to validate these observations in additional clinical cohorts. In addition, biological characterization of relevant loci is required to understand how methylation at particular loci contributes to or influences breast cancer prognosis.
Genome wide DNA methylation in prostate cancer
DNA methylation profiles that discriminate tumor from non-malignant prostate tissue Eight genome wide DNA methylation studies have compared non-malignant and tumor tissue. Chung et al. (2008) used methylated CpG island amplification coupled with representational difference analysis of prostate cancer cell lines (pooled DU145, PC3, and LNCaP) and identified eight genes with promoter hypermethylation (Table 2) . These genes were validated in prostate cancer compared with non-malignant tissue (nZ20) and were re-expressed by the DNA methylation inhibitor 5-aza-2 0 -deoxycytidine (5-aza). FAM84A (NSE1) and SPOCK2 hypermethylation was the optimal biomarker combination in differentiating cancer from nonmalignant tissue (sensitivity, 80%; specificity, 95%; and accuracy, 96%; Chung et al. 2008) . Kim et al. (2011d) combined genome wide DNA methylation and gene expression in pooled LNCaP-FGC, DU-145, and PC-3 cells compared with RWPE-1 non-malignant cultured prostate cells (Table 2) . Three genes exhibited concordant methylation and expression changes, had a CpG island, and enhanced expression after 5-aza treatment. In clinical samples, EFEMP1 methylation was the optimal marker to differentiate prostate cancer from benign prostatic hyperplasia (sensitivity, 95.3% and specificity, 86.6%). EFEMP1 gene expression was also reduced in an independent prostate cancer cohort (Kim et al. 2011d) . Kron et al. (2009) performed differential methylation hybridization (DMH) of prostate cancer samples (Table 2) . Of the genes hypermethylated in prostate cancer, HOXD3 and BMP7 were validated by 5-aza re-expression in vitro in DU145 cells (Kron et al. 2009 ). These studies identified several candidate genes with differential DNA methylation and gene expression between cancerous and non-malignant tissue. Future functional studies of these genes will clarify their role in prostate tumorigenesis. Kobayashi et al. (2011) identified 87 CpG biomarkers in a large clinical prostate cancer cohort, almost all of which were hypermethylated in cancer (83/87; Table 2 ). Kim et al. (2011c) identified 1034 differentially methylated genes in prostate cancer ( Table 2 ). The highest functional network identified from these genes was 'Cancer, Cellular Movement, Hematological System Development and Function', with TNFa as the central mediator. Despite methylation discovery being performed with a single pooled sample each for tumor and non-malignant, of ten genes with promoter hypermethylation selected for expression analysis in an independent patient cohort (nZ17), most genes showed reduced expression, supporting the methylation results reported by Kim et al. (2011c) . Coolen et al. (2010) mined public gene expression databases to identify candidate regions of long-range epigenetic silencing (LRES; Table 2 ). Regions were classified as candidates for LRES if they i) contained four or more consecutive repressed or silent genes in two prostate cancer clinical data sets; ii) essentially lacked upregulated probes, and iii) had probes that were upregulated in at least 2/4 prostate cancer cell lines after 5-aza (Coolen et al. 2010) . Genome wide methylation in LNCaP and PrEC was analyzed by MeDIP-chip, and results were presented for seven candidate regions. Hypermethylation was identified for a number of individual genes and the HOX-A and SERPINB gene families, with limited validation in clinical samples (Coolen et al. 2010) . Kim et al. (2011a) identified 2481 cancer-specific methylation events in clinical cancer (Table 2 ) and coupled this with gene expression. Methylation, 5-aza re-expression, and chromatin mapping data from LNCaP and PrEC cells, together with clinical methylation and expression data, also demonstrated that promoter methylation regulates alternative transcript expression for the known cancer-related genes RASSF1, NDRG2, and APC (Kim et al. 2011a) . A recent study not only identified differential DNA methylation changes between non-malignant and tumor tissue but also identified DNA methylation changes in histologically non-malignant tissue adjacent to tumor (Yang et al. 2013) . This highlights the critical nature of sample choice, particularly with respect to non-malignant tissue for comparison. It also suggests that some DNA methylation 5-aza, 5-aza-2 0 -deoxycytidine; aCGH, array comparative genomic hybridization; BCR, biochemical recurrence; BPH, benign prostatic hyperplasia; CRPC, castrate-resistant prostate cancer; DMH, differential methylation hybridization; FFPE, formalin fixed, paraffin embedded; GE, gene expression; LRES, longrange epigenetic silencing; MCA-RDA, methylated CpG island amplification coupled with representational difference analysis; MeDIP, methyl DNA immunoprecipitation using a 5MeC MAB; NGS, next-generation sequencing; NM, non-malignant; PCa, prostate cancer; PrEC, cultured non-malignant prostate epithelial cell line. If the information was available, details of the type of tissue used were also included.
changes are seen very early in the tumorigenesis process, or alternatively 'spread' from the tumor into the surrounding tissue, potentially promoting a suitable environment for tumor growth. Future studies should investigate these possibilities. The studies discussed here in general included limited validation of DNA methylation; both in terms of clinical cohorts and relationship with other genome wide data such as chromosome copy number, gene expression, and re-expression by demethylating agents. Future work should include more systematic validation of the genome wide DNA methylation analyses currently reported. Kim et al. (2011a) analyzed DNA methylation of four metastatic prostate cancer samples; however, results for these samples were grouped with other cancers making analysis difficult. Friedlander et al. (2012) integrated genome wide chromosome copy number, gene expression, and DNA methylation across metastatic CRPC compared with primary cancer and benign prostate. Sixteen genes had methylation and copy loss in the same tumor in 66% or more of samples, and methylation changes were more common than copy number alteration in CRPC. Moreover, androgen biosynthesis, the p53 pathway, and the insulinlike growth factor 1-protein kinase B signaling cascade were identified as pathways of genes frequently altered by aberrant copy number or DNA methylation changes (Friedlander et al. 2012) . Androgen biosynthesis is a key mechanism for maintaining androgen signaling following androgen deprivation therapy (Cai & Balk 2011) , and loss of p53 plays an important role in regulating AR activity across the genome (Guseva et al. 2012) . Together, this re-iterates the potential of DNA methylation to identify novel therapeutic targets in advanced prostate cancer.
DNA methylation profiles in CRPC
DNA methylation profiles in prostate cancer progression and recurrence Kim et al. (2011a) reported that total promoter-associated CpG island methylation increases in parallel with prostate cancer progression but did not correlate this increased methylation with any specific individual genomic loci. The first genome wide DNA methylation study to identify individual CpGs associated with prostate cancer progression was reported by Kron et al. (2009) , who performed DMH of pure primary gleason pattern 3 (PP3) and PP4. From the top 100 differentially methylated genes, BMP7 and HOXD3 were selected for analysis as potential biomarkers based on their putative and known biological functions. Further research could investigate the functional role of differentially methylated genes identified in this study and also identify whether combinations of these could act as biomarkers of disease progression.
Two subsequent studies have identified panels of differentially methylated CpGs associated with progression or recurrence in prostate cancer clinical cohorts. Kobayashi et al. (2011) identified 69 CpGs associated with time to biochemical recurrence. These CpGs were located in the promoters of both novel and known cancer-related genes; further study is required to investigate the function of genes without a previously identified role in cancer. In the same study, Gleason grade could not be distinguished by methylation profile. Similarly, Mahapatra et al. (2012) found 75 genes differentially methylated between recurrence and no recurrence, 68 genes differentially methylated between systemic recurrence and local recurrence, and 16 genes differentially methylated between clinical recurrence and biochemical recurrence. Overall, there were fewer genes methylated in patients with clinical recurrence compared with patients with only biochemical recurrence (Mahapatra et al. 2012) . Validation of 14 genes in an independent cohort (nZ20 per group) supported the genome wide data. However, the cohorts in each of these studies were small and validation is required in larger independent cohorts.
Similarities between DNA methylation profiles in breast and prostate cancers
We have performed a meta-analysis of the currently reported genome wide DNA methylation studies in breast and prostate cancers. We identified genes or gene families (HUGO Gene Nomenclature, http://www.genenames.org/) commonly targeted for aberrant DNA methylation as those that were identified in at least four different studies (Table 3 ). In performing this meta-analysis, we utilized the gene lists provided with the publication. We note that this analysis was biased by differences between studies, the biggest difference being whether data was just genome wide DNA methylation or whether genes were identified by other filtering processes such as combining DNA methylation with gene expression or CNV. From 22 breast cancer studies, we identified 425 genes that were commonly subject to aberrant methylation. Ninety-five genes were commonly aberrantly methylated in prostate cancer. The lower number of genes identified in prostate cancer is most likely due to the lower number of genome wide DNA methylation studies currently published for Homeobox gene/gene family (Fig. 1) . Surprisingly, there were 54 genes in common between the breast and prostate cancer gene lists (Fig. 2) . A small number of these genes identified as aberrantly methylated in both breast and prostate cancers have previously been shown to be methylated in breast, prostate, and other cancers: APC, CDKN2A, GSTP1, RASSF1, RUNX3, S100A2, SFRP1, and WT1 (Table 4) . However, a large number of these genes have not been previously shown to be methylated in breast and prostate cancers or cancer in general, including genes from the SLC family. Interestingly, the Ingenuity Pathway Analysis of genes identified with aberrant methylation in breast cancer (red), prostate cancer (green), and both (yellow). The top network identified from the genes aberrantly methylated in four or more studies in breast and prostate cancers was Embryonic Development, Organismal Development, Cancer.
only study to investigate both breast and prostate cancers identified four genes to be hypermethylated in both cancers; one of these four genes was a member of the SLC family (Chung et al. 2008 Genes commonly subject to aberrant DNA methylation in breast cancer
Numerous breast cancer genome wide DNA methylation studies identified homeobox genes as differentially methylated between non-malignant and tumor or associated with hormone receptor status or breast cancer prognosis (Ordway et al. 2007 , Novak et al. 2008 , Tommasi et al. 2009 , Van der Auwera et al. 2010 , Fackler et al. 2011 , Fang et al. 2011 , Hill et al. 2011 , Kamalakaran et al. 2011 ; Table 3 ). Other gene families that were commonly identified as differentially methylated between nonmalignant and tumor included transcription factors (FOX, KLF, PRDM, ZBTB, and ZNF) and gene families involved in cell transport of proteins or vesicles (RAB and SLC) or involvement in cell adhesion (CDH and PCDH) ( Kamalakaran et al. 2011) . The ST8 family of ovarian cancer tumor suppressor genes was commonly identified in non-malignant vs tumor and prognosis as was the RECK tumor suppressor gene (Table 3) . IPA of the genes methylated in breast cancer identified some biological functions, such as posttranslational modification and lipid metabolism, that were only identified in breast cancer and not in prostate cancer. This may be due to the differences in the gene list size between breast and prostate cancers. In terms of the canonical pathways, the top ones for breast cancer-specific genes were transcriptional regulatory network in embryonic stem cells and caveolar-mediated endocytosis signaling. Given that the pathways and gene families do not appear to have a strong link to hormone metabolism or signaling, it is Figure 2 Venn diagram showing the genes commonly altered by DNA methylation in breast (red) and prostate (green). Fifty-four genes were common between breast and prostate cancers. Table 4 Genes aberrantly methylated in breast and prostate cancers.
Homeobox genes are in bold.
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Genes identified as commonly targeted by DNA methylation in prostate cancer
There was substantial overlap between different studies of genome wide DNA methylation in prostate cancer (Table 3) . GSTP1 frequently exhibits prostate cancerspecific gene promoter methylation (Goering et al. 2012) , and this was reflected in the studies reviewed here (Table 3) . The homeobox or T-box gene families were commonly identified in cancer compared to non-malignant and during progression (Kron et al. 2009 ). Despite the limitations of this study introduced using pooled lymphocytes as a reference, many homeobox genes were also identified in other studies (Kim et al. 2011a , Friedlander et al. 2012 .
Where studies had more similarities, there was greater overlap. For example, in prostate cancer vs non-malignant, 16/25 genes identified by Mahapatra et al. (2012) overlapped with those identified by Kobayashi et al. (2011) . Similarly, there were many common genes in studies where cell lines were used. This suggests that the degree of variation in methylation between samples is sufficiently small that genome wide DNA methylation analysis techniques can reliably and robustly detect methylation changes. The degree of similarity observed also reflects the variability within each disease state, with less overlap identified between studies of prostate cancer progression and recurrence than for cell line or cancer vs nonmalignant. IPA identified biological functions associated with genes methylated in prostate cancer (Inflammatory Response and Immune Cell Trafficking) that were not evident with genes from breast cancer. The top canonical pathways for prostate cancer were bladder cancer signaling and Wnt/b-catenin signaling.
Future directions
While this review demonstrates that genome wide DNA methylation analysis in breast and prostate cancers can provide novel data and identify gene pathways not usually associated with these cancers, further study is required. First, it is clear that studies that integrate multiple data sources will produce the highest quality targets. Additional studies that integrate genome wide DNA methylation, gene expression, CNV, and analysis of other histone modifications are essential in prostate cancer, and to a lesser extent, breast cancer. These studies must be performed in appropriately powered clinical cohorts with the relevant patient samples. Studies of this nature should produce an unbiased, high-quality 'roadmap' of all sites in the genome that are under the influence of DNA methylation. Secondly, a meta-analysis of currently reported studies, using the raw data, should be conducted. While the meta-analysis presented here demonstrates that there are novel and overlapping genes/gene families subject to aberrant DNA methylation in breast and prostate cancers, careful comparison of this Figure 3 Genomic features of the 7p15.2 chromosomal region. The genes commonly altered by methylation in breast and prostate cancers were enriched for this region, which contains the HOXA gene cluster. Genes in the region and corresponding CpG islands are shown using the human genome browser at UCSC (http://genome.ucsc.edu/; Kent et al. 2002) .
data with genome wide DNA methylation data from other cancers is essential. This will minimize variation between studies resulting from inconsistent statistical analyses and generate an unbiased list of candidate genes, some of which are likely to be breast and/or prostate specific, making them good candidates for being drivers of disease. Drivers of disease are also potential therapeutic candidates for late-stage breast or prostate cancer, for which there are currently limited therapeutic options.
Conclusion
Genome wide methylation studies in breast and prostate cancers have identified in an unbiased manner genes and gene families with aberrant methylation in non-malignant vs tumor, or with cancer progression or associated with hormone receptor status. This demonstrates the potential of these techniques to enhance our understanding of what controls gene expression in hormonally regulated cancers. Our analysis of the genes identified with aberrant methylation in breast and prostate cancers clearly showed that there was substantial overlap between genes identified across different studies, both within and between cancer types. The observed overlap between breast and prostate cancers may be a result of common underlying hormonal growth pathways, although this requires further analyses.
In conclusion, the studies reviewed here demonstrate the potential of identifying epigenetically regulated genes that are involved in cancer initiation or progression, and therefore biomarkers of prognosis and diagnosis, and that may be targets for epigenetic-modifying agents. However, further validation in additional clinical cohorts is required to confirm the targets of aberrant methylation in breast and prostate cancers. In addition, methylation results need to be linked to alterations in gene expression, chromosome copy number alterations, and other epigenetic marks, all of which work together to contribute to the transcriptional picture of a cell. Only with a fully integrated, genome wide analysis, can the downstream effects of these genetic and epigenetic changes on breast and prostate cancer cells be determined. In doing so, we will identify the key drivers in hormonal tumorigenesis and elucidate key targets for chemoprevention and therapeutics.
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